Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Finished

EPIC-CROWN-2 Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2–VOC

Coordinator
Fabentech, France
Runs
1 June 2021 to 30 November 2023
Status
Finished
EU funding
€9.1m
Total cost
€9.2m
Partners
5 organisations in 4 countries
Type
Research and Innovation Action
Grant agreement
101046084

What the project is doing

In the project's own words, from its summary on CORDIS.

The highly contagious SARS-CoV-2 virus has generated an unprecedented pandemic with global dramatic public health and socio-economic consequences need an urgent mitigation. Despite the progression of the global use of efficient vaccines, an increased transmissibility of variants of concern (VOC) is predominantly observed. The reduced sensitivity of VOCs to neutralizing response could become a serious obstacle for efficient vaccination.

In the absence of approved specific antiviral therapies for vaccinated-non-responders and the scarce anti-inflammatory therapies, passive immunotherapies with polyclonal immunoglobulins could be considered a part of the solution. The main objective of EPIC-CROWN is to rapidly assess, in multicentric clinical trials (phase IIa, 16 patients and IIb, 400 patients), an EMA-authorized antiviral immunotherapy based on potent and broad equine neutralizing anti-SARS-CoV-2 polyclonal F(ab’)2 antibodies in COVID-19 patients, including VOC carriers.

In order to save lives and reduce the use and costs of critical care, this therapeutic solution expect to reduce at least by 50% ICUs admissions and a highly significant mortality rate of treated patients. To optimize the indications for the treatment, potency and breath of F(ab’)2 against variants will be assessed in in vitro and in an animal model as well as prospective studies will respectively be done on immune assessment in treated patients and on mitigation of exacerbated immune responses in vivo.

Fab’entech will coordinate EPIC-CROWN-2 formed by outstanding experts in different project domains that include clinical trials (HISS, Greece), virology (IMAS12, Spain), and immunopathology models and mitigation (BNITM, Germany - IRD, France). Most of them having already been working together in European projects. Importantly, EPIC-CROWN-2 will be integrated as part of both the large European trial network EU-RESPONSE and the multinational European Adaptive Platform Trial “Solid Act"".""

Topics

Who is involved

OrganisationCityCountryRole
FabentechLyonFranceCoordinator
Bernhard-Nocht-Institut Fuer TropenmedizinHamburgGermanyParticipant
Elliniko Instituto Meletis Tis SipsisAthensGreeceParticipant
Fundacion Para La Investigacion Biomedica Del Hospital Universitario 12 De OctubreMadridSpainParticipant
Institut De Recherche Pour Le DeveloppementMarseilleFranceParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI